Inherited thrombophilia: An update

Clinical Laboratory

Volumn 51, Issue 7-8, 2005, Pages 357-365

  Franchini, Massimo ^a,b   Veneri, Dino ^a,b  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Arterial thrombosis; Coagulation; Genetics; Therapy; Thrombophilia; Venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; HEPARIN; PROTHROMBIN; WARFARIN;

ACTIVATED PROTEIN C RESISTANCE; ALLELE; ANTITHROMBIN DEFICIENCY; CARDIOVASCULAR DISEASE; DYSFIBRINOGENEMIA; FIBRINOGEN BLOOD LEVEL; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; HYPERHOMOCYSTEINEMIA; PREGNANCY; PREVALENCE; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; PROTEIN VARIANT; REVIEW; RISK FACTOR; SCREENING TEST; SKIN NECROSIS; THROMBOEMBOLISM; THROMBOPHILIA;

BLOOD COAGULATION DISORDERS, INHERITED; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; CARDIOVASCULAR DISEASES; FAMILY HEALTH; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; RISK FACTORS; THROMBOPHILIA;

EID: 23844479710     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Lane D, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: Part I. Thromb Haemost 1996; 76: 651-62.
2. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 13: 516-30.
3. De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes and management. Blood 1996; 87: 3531-44.
4. Khan F, Pechet L, Snyder LM. The laboratory of hypercoagulability: a review of present-day techniques. J Thromb Thrombolysis 1998; 5: 269-76.
5. Schafer AI, Levine MN, Konkle BA, Kearon C. Thrombotic disorders: diagnosis and treatment. Hematology (Am Soc Hematol Educ Program) 2003; 520-39.
6. Walker ID, Greaves M, Preston FE. Investigation and management of heritable thrombophilia. Brit J Haematol 2001; 114: 512-28.
7. Buchanan GS, Rodgers GM, Branch DW. The inherited thrombophilias: genetics, epidemiology, and laboratory evaluation. Best Pract Res Clin Obst Gynecol 2003; 17: 397-411.
8. Spencer F, Becker RC. Diagnosis and management of inherited and acquired thrombophilias. J Thromb Thrmobolysis 1999; 7: 91-104.
9. Samama M, Gerotziafas G, Conard J, et al. Clinical aspects and laboratory problems in hereditary thrombophilia. Haemostasis 1999; 29: 76-99.
10. Crowther MA, Kelton JG. Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposal classification system. Ann Intern Med 2003; 138: 128-34.
11. Cumming AM, Shiach CR. The investigation and management of inherited thrombophilia. Clin Lab Haem 1999; 21: 77-92.
12. Tripodi A, Mannucci PM. Laboratory investigation of thrombophilia. Clin Chem 2001; 47: 1597-1606.
13. Simioni P. The molecular genetics of familial venous thrombosis. Bailliere's Clin Haematol 1999; 12: 479-503.
14. Griffin JH, Evatt B, Zimmerman TS, et al. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68: 1370-3.
15. Franco RF, Reitsma PH. Genetic risk factors of venous thrombosis. Hum Gen 2001; 109: 369-84.
16. Bauer KA. The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Ann Int Med 2001; 135: 367-73.
17. Comp PC, Esmon CT. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 1984; 311: 1525-8.
18. Schwartz H, Fischer M, Hopmeier P, Batard MA, Griffin HH. Familial protein S deficiency is associated with recurrent thrombosis. Blood 1984; 64: 1297-300.
19. Borgel D, Gandrille S, Aiach M. Protein S deficiency. Thromb Haemost 1997; 78: 351-6.
20. Dahlback B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 1994; 91: 1396-400.
21. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
22. Castaman G, Faioni EM, Tosetto A, Bernardi F. The factor VHR2 haplotype and the risk of venous thrombosis: a meta-analysis. Haematologica 2003; 88: 1182-89.
23. Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 1999; 130: 643-50.
24. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
25. Roberts HR, Stinchcombe TE, Gabriel DA. The dysfibrinogenemias. Brit J Haematol 2001; 114: 249-57.
26. Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost 2003; 89: 601-9.
27. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987; 258: 1183-6.
28. Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-7.
29. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-5.
30. Yarnell JW, Baker IA, Sweetnam PM, et al. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies. Circulation 1991; 83: 836-44.
31. Assmann G, Cullen P, Heinrich J, Schulte H. Hemostatic variables in the prediction of coronary risk: results of the 8 year follow-up of healthy men in the Munster Heart Study (PROCAM). Prospective Cardiovascular Munster Study. Isr J Med Sci 1996; 32: 364-70.
32. Kamath S, Lip GY. Fibrinogen: biochemistry, epidemiology and determinants. QJM 2003; 96: 711-29.
33. Mannila MN, Eriksson P, Lundman P, et al. Contribution of haplotypes across the fibrinogen gene cluster to variation in risk of myocardial infarction. Thromb Haemost 2005; 93: 570-7.
34. Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost 1999; 81: 165-76.
35. Arruda VR, von Zuben PM, Chiaparini LC, Annichino-Bizzacchi JM, Costa FF. The mutation Ala677 in the methylene tetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Thromb Haemost 1997; 77: 818-21.
36. Robetorye RS, Rodgers GM. Update on selected inherited venous thrombotic disorders. Am J Hematol 2001; 68: 256-68.
37. Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII end the risk of recurrent venous thrombembolism. N Engl J Med 2000; 343: 457-62.
38. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-5.
39. Kamphuisen PW, Houwing-Duistermaat JJ, van Houwelingen HC, Eikenboom JCJ, Bertina RM, Rosendaal FR. Familial clustering of factor VIII and von Willebrand factor levels. Thromb Haemost 1998; 79: 323-7.
40. O'Donnell J, Mumford AD, Manning RA, Laffan M. Elevation of FVIII in venous thrombembolism is persistent and independent of the acute phase response. Thromb Haemost 2000; 83: 10-3.
41. Vossen CY, Conard J, Fontcuberta J, et al. Familial thrombophilia and lifetime risk of venous thrombosis. J Thromb Haemost 2004; 2: 1526-32.
42. Bauer KA. Management of thrombophilia. J Thromb Haemost 2003; 1: 1429-34.
43. Ginsberg JS, Bates SM. Management of venous thromboembolism during pregnancy. J Thromb Haemost 2003; 1: 1345-42.
44. Eldor A. Thrombophilia and its treatment in pregnancy. J Thromb Thrmobolysis 2001; 12: 23-30.
45. Gerhardt A, Scharf RE, Beckmann MW, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000; 342: 374-80.
46. Friederich PW, Sanson BJ, Simioni P, et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med 1996; 125: 955-60.
47. Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003; 361: 901-8.
48. Martinelli I, De Stefano V, Taioli E, Paciaroni K, Rossi E, Mannucci PM. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost 2002; 87: 791-5.
49. Villarreal C, Garcia-Aguirre G, Hernandez C, Vega O, Borbolla JR, Collados MT. Congenital thrombophilia associated to obstetric complications. J Thromb Thrombolysis 2002; 14: 163-9.
50. Regan L, Rai R. Thrombophilia and pregnancy loss. J Reprod Immunol. 2002; 55: 163-80.
51. Kujovich JL. Thrombophilia and pregnancy complications. Am J Obstet Gynecol 2004; 191: 412-24.
52. Brenner B, Grabowski EF, Hellgren M, et al. Thrombophilia and pregnancy complications. Thromb Haemost 2004; 92: 678-81.
53. Fruchart J-C, Nierman MC, Stroes ESG, Kastelein JJP, Duriez P. New risk factors for atherosclerosis and patient risk assessment. Circulation 2004; 109(Suppl. III): 15-9.
54. Ardissino D, Mannucci PM, Merlini PA, et al. Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood 1999; 94: 46-51.
55. Voetsch B, Loscalzo J. Genetics of thrombophilia: impact on atherogenesis. Curr Opin Lipidol 2004; 15: 129-43.
56. Klerk M, Verrhoef P, Clarke R, et al. MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002; 288: 2023-31.
57. Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis 2003; 169: 203-14.
58. de Maat MP, Kastelein JJ, Jukema JW, et al. -455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. REGRESS group. Arterioscler Thromb Vasc Biol 1998; 18: 265-71.
59. Huber K, Christ G, Wojta J, Gulba D. Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001. Thromb Res 2001; 103 (Suppl 1): S7-19.
60. de la Peña-Diaz A, Izaguirre-Avila R, Angles-Cano E. Lipoprotein Lp(a) and atherothrobotic disease. Arch Med Res 2000; 31: 353-9.